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ABSTRACT 
Objective  
Malignant Pleural Mesothelioma (MPM) has a poor prognosis and high symptom burden. RESPECT-Meso was 
a multicentre randomised study examining the role of early specialist palliative care (SPC) on quality of life 
(QoL) with MPM. This is a post-hoc exploratory analysis of the symptom burden and unmet needs identified 
from RESPECT-Meso participants.  
 
Methods 
Exploratory analysis from 174 participants using the General Health Status (GHS) measure (from the EORTC 
QLQ-C30 QoL questionnaire) and 87 participants using validated assessment questionnaires in those 
randomised to SPC.  Eligibility for the study included confirmed MPM with diagnosis <6 weeks prior, 
performance score (PS) 0 or 1, no significant physical or psychological comorbidity. Cox proportional hazards 
models were derived to examine for relationships with survival. Free text was assessed using content analysis, 
looking for common themes and words. 
 
Results:  
Participants were predominantly male (79.9%), mean age 72.8 years, PS was 0 in 38%, 78% of MPM was 
epithelioid. At least three symptoms were reported in 69.8% of participants, including fatigue (81%), dyspnoea 
(73.3%), pain (61.2%), weight loss (59.3%). Anxiety was reported by 54.7% of participants, 52.3% low mood 
and 48.8% anhedonia symptoms. After multivariable adjustment, only pain remained statistically significant 
with a hazard ratio (HR) 2.9 (95% CI 1.3-6.7; p=0.01). For each 1 unit increase in GHS score, the HR for death 
was 0.987 (0.978-0.996; p=0.006), indicating a worse reported QoL is related to shorter survival.  
 
Unmet needs were common: 25.9% wanted more information about their condition, 24.7% about their care and 
21.2% about their treatment. 79.1% were concerned about the effect of their illness on family.  
 
Conclusion   
There is a high symptom burden in mesothelioma despite good baseline performance status. A worse QoL is 
associated with a worse survival. Unmet needs are common, perhaps highlighting a need for improved 
communication and information sharing.    
INTRODUCTION  
Malignant pleural mesothelioma (MPM) is an aggressive cancer arising from mesothelial cells caused by 
exposure to asbestos fibres. MPM has a median survival of less than 12 months 1 with the majority of 
individuals presenting with locally advanced disease and a high symptom burden 2-4. Doublet chemotherapy has 
been shown to improve quality of life but only adds a survival benefit of a few months 5. Newer treatments such 
as immunotherapy and anti-angiogenesis agents have shown promise, however results have been disappointing 
to date 6,7,8.  
 
A high symptom burden can significantly impair health related quality of life (HRQoL) 2,9,10 and baseline 
HRQoL has been shown to be a significant independent prognostic factor across multiple tumour types 
including non-small cell lung cancer, colorectal cancer and mesothelioma 2,3,11-16. Additionally, these studies 
have demonstrated that specific symptoms or patient-related factors may influence prognosis. Two separate 
meta-analyses have found that certain HRQoL parameters, such as appetite loss and pain, can provide 
significant prognostic value 14,15.  Furthermore, advanced cancer participants have unmet needs across a 
multitude of domains in addition to physical, including psychological, functional, financial and informational 
9,17. Two systematic reviews examined unmet needs across multiple cancer types and consistently found that the 
most prominent unmet needs were of emotional support, fatigue and inadequate information in regard to 
treatment 9,17.  
 
The RESPECT-Meso study was a large multicentre randomised study examining the role of regular early 
specialist palliative care on the HRQoL of individuals with MPM 18. All participants were assessed at baseline 
for HRQoL using the European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30). The participants randomised to early SPC also had further 
assessments at baseline – the Sheffield Profile for Assessment and Referral to Care tool (SPARC) and the 
Edmonton Symptom Assessment System (ESAS).  
 
The primary outcome for RESPECT-Meso was not met as there was no statistically significant difference in 
HRQoL between arms. This study presents the planned exploratory analyses examining the QoL data, symptom 
scores and analyses of unmet needs. 
 
METHODS  
The RESPECT-Meso study design, eligibility criteria, and statistical analyses have been described in detail 
previously 18,19 and are summarised below. 
Trial design and participants  
RESPECT-Meso was a multicentre, randomised, non-blinded, parallel group-controlled trial. The trial recruited 
174 participants from 19 secondary and tertiary hospitals across the UK and one tertiary hospital site in Western 
Australia. Potential participants were required to have Eastern Co-operative Oncology Group (ECOG) 
performance status of 0 to 1, a new histological or cytological diagnosis of malignant pleural mesothelioma, and 
able to consent in English. Participants with history of malignancy within five years, significant physical or 
psychiatric co-morbidity, high symptom burden at diagnosis, recent thoracic surgery or already commenced 
systemic anticancer therapy for mesothelioma were excluded.  
 
Participants randomised to the intervention arm were referred to SPC within six weeks of diagnosis, regardless 
of perceived need and were seen every four weeks throughout the study period. Participants in the control arm 
received standard care, including standard referral to palliative services if indicated. 
 
Assessment 
All participants completed the EORTC QLQ-C30 at baseline (pre randomisation) and every four weeks until 
twenty-four weeks or drop out. The EORTC QLQ-C30 is a validated tool that incorporates functional scales 
including physical, cognitive and emotional, and symptom scales including fatigue, pain and nausea as well as a 
global health and HRQoL scale14. All participants were asked at baseline, twelve- and twenty-four -week clinic 
visits whether they reported pain.  
 
Further, all participants randomised to the intervention arm underwent the SPARC and ESAS tools at initial 
consultation to ensure a standard approach to SPC. The ESAS is a short visual analogue scale across eight 
different symptom domains with two extra questions addressing patient-nominated “other symptoms” and 
location of pain 20. SPARC is a multidimensional screening tool with 45 questions across multiple domains 
including communication, physical symptoms, psychological issues, religious and spiritual issues, 
independence, family and social issues and treatment issues.21.  
 Statistical methods  
Participant baseline demographic characteristics were reported using frequency and percentages for categorical 
data and mean and standard deviation for continuous data with a normal distribution. Exploratory analysis was 
performed using the General Health Status (GHS) measure derived from the EORTC QLQ-C30 QoL 
questionnaire. Univariate and multivariate Cox proportional hazards models were derived for the transformed 
GHS, physical symptom scores (reduced appetite, weight loss, pain, dyspnoea and fatigue) and composite 
measures of physical, psychological and social factors to examine for any relationship with survival. 
Spearman’s rho was used to examine correlation between the measures.  
 
Survival was analysed using a joint modelling approach with QoL, incorporating outcome measurements at 
various time points and survival time, with surviving participants censored at their 24-week visit or date of last 
visit if they dropped out earlier than 24 weeks. Results of the ESAS and SPARC were reported using frequency 
and percentages for categorical data. Correlation between ESAS and SPARC common domains were assessed 
using Pearson’s Chi test. Free text was assessed using content analysis, looking for common themes and words. 
Statistical analyses were performed using Stata V.15.1 (StataCorp LP, College Station, TX, USA). Additional 
figures were produced using the Bioinformatics and Evolutionary Genomics Venn diagram tool (Ghent 
University, Gent, BELGIUM). 
 
RESULTS  
The RESPECT-Meso study randomised 174 participants, 87 to each arm with exploratory analysis in the 
intention-to-treat (ITT) population. The median follow-up time was 41.1 weeks (range 2-133 weeks). Baseline 
demographic and clinical characteristics of both study arms were well matched and are presented in table 1.  
The baseline EORTC QLQ C30 was completed by 173 participants; 147 at 12 weeks, and 125 participants at 24 
weeks. Eighty-seven participants were allocated to the early SPC and 86 participants completed the SPARC and 
ESAS assessments.  
 
Mean (SD) baseline GHS score in the standard care arm was 66.9 (22.6) and in the intervention arm was 66.1 
(20.0). From the QLC-C30, dyspnoea was reported as ‘quite/very much’ by 53/173 (30.6%) participants, pain 
‘quite/very much’ by 40/170 (23.5%) and fatigue ‘quite/very much’ by 47/172 (27.3%).  
 Physical symptoms  
The three most common symptoms on the EORTC QLQ-C30 were pain (n=40, 24%), dyspnoea (n=53, 31%) 
and fatigue (n=47, 27%). The reported symptom burden was similar between treatment groups at all time points 
and did not change significantly over time (data not presented).  
 
Using the ESAS tool, n=84 (97.7%) participants presented with at least 1 symptom and n=60 (69.8%) with 3 or 
more symptoms. The frequency and severity of symptoms are shown in figure 1. The most common symptom 
reported was fatigue (n=70, 81.4%), followed by dyspnoea (n=63, 73%) and pain (n=52, 60%). On content 
analysis of the “other” symptoms (n=13), the most common was constipation (n=7) with other complaints 
including bladder incontinence (n=1), frustration (n=1), confusion (n=1), cold sores (n=1), diarrhoea (n=1) and 
dysphagia (n=1). The responses to the ESAS by symptoms are presented in figure 1.  
 
Using the SPARC tool, 86 participants reported a median of 9 symptoms (range 0-18) of the 22 physical 
symptoms interrogated. Dyspnoea (n=75, 87%), fatigue (n=74, 86%) and pain (n=65, 76%) were the most 
commonly reported symptoms. Dyspnoea was also the most common symptom reported as “very much” (n=10).  
 
There was no difference in reporting of the common symptoms between the ESAS and SPARC. The total ESAS 
and SPARC scores demonstrated a strong correlation with GHS (R2=0.2; p<0.01 and R2=0.3; p<0.01 
respectively). 
 
Pain 
For all participants, 100 of 174 (57%) reported pain at baseline, 84 of 154 (55%) at 12 weeks and 74 of 127 
(58%) at 24 weeks, (p value for trend 0.79). In the intervention arm, 52 participants (59.7%) reported pain on 
the ESAS scale, but only 46 participants (53%) marked a location of pain on the diagram or wrote in their 
location of pain. Of the 46 participants that identified a location of pain, most participants noted multiple sites of 
pain with a total of 70 locations of pain. 35 (50%) participants reported pain in the chest or chest wall region, 
with 23 (33%) reporting back pain and 12 (17%) reporting pain elsewhere.  
 
Quality of life, symptoms and survival  
Overall survival was assessed in relation to the three most common physical symptoms: dyspnoea, pain and 
fatigue. For all three symptoms, the estimated median survival times were higher in the low severity category and 
the log rank test suggested significant differences in survival between participants with high and low symptom 
severity (see table 2). The estimated HR for both dyspnoea and pain was 1.7 (95% CI: 1.1-2.6) i.e. the hazard for 
death was 70% higher in those in the high severity group. The HR for fatigue was 1.9 (95% CI: 1.3-3.0). 
For each 1 unit increase in GHS score, the estimated hazard ratio (HR) for death was 0.987 (95% CI: 0.978, 
0.996), p=0.006. Figure 2 demonstrates the relationship of GHS with survival for all participants, suggesting a 
higher baseline HRQoL is associated with a longer survival. The univariable HR (for death) of reduced appetite 
was 2.3 (95% CI 1.2-4.4; p=0.01); loss of weight 1.8 (0.98-3.4; p=0.06); dyspnoea 1.9 (1.1-3.5; p=0.03); pain 
1.5 (0.8-2.9; p=0.19); and fatigue 2.5 (1.4-4.4; p=0.003). After multivariable adjustment for age, gender, PS, 
chemotherapy, sarcomatoid containing histology, comorbidities and baseline GHS, only pain remained 
statistically significant with a HR 2.9 (1.3-6.7; p=0.01). 
 
Communication and information  
Participants stated that they were able to discuss their condition with their doctor (n=61/87), community nurses 
(n=22), hospital/specialist nurses (n=65) and family (n=82). In the free text, 34 participants (40%) reported 
discussing with friends and 7 participants reporting discussion with asbestos/mesothelioma support groups. 
Religious support was sought by 7 participants, 6 participants spoke with a social worker, 1 to a clinical 
psychologist, and 1 with hospice staff. Figure 3 demonstrates the interrelationship of whom the participants 
were able to discuss their condition with.  
 
With regard to the areas of concern for participants, 34 (40%) participants were concerned about the side effects 
of treatment. Thirty-three (38%) participants were concerned about the long-term effects of treatment. Twenty-
two (26%) participants were concerned about both. Participants felt that they needed more information about 
their condition (n=22) and care (n=21). In the free text section of more information or questions, 29 participants 
wrote that they required more information about prognosis and palliative care/end of life care (n=14), treatment 
(n=10), symptoms (n=10) and diagnosis (n=5). Of those asking about diagnosis, 1 requested a second opinion to 
confirm diagnosis, 2 were unsure of extent of disease and 2 were frustrated and angry at delays in diagnosis.   
 
Psychological and Spiritual needs 
Anxiety was among the most common psychological symptom from the SPARC questionnaire with 47 out of 86 
(55%) responses, although of these, most participants reported a low level of severity in anxiety (n=35, “a little 
bit”). Low mood (n=45, 52%), feeling like “everything is an effort” (n=42, 49%) and inability to concentrate 
(n=36, 42%) were the next most common symptoms. Only 4 participants reported high levels (“very much”) of 
psychological symptoms – these were low mood (n=1) and effect on sex life (n=3). 29 (34%) participants 
reported worrying about death and dying. Only 2 participants reported inadequate needs met in terms of 
religious or spiritual support.  
 
Independence and Support/Family   
Most participants were concerned about the impact of their disease on family (n=68). Only 11 participants 
reported being concerned about their support network being unable to care adequately for them. 32 participants 
reported fears about losing independence, 36 participants reported concerns about losing ability to perform 
activities of daily living (ADLS), and 20 reported concerns about performing household tasks. Few participants 
reported concerns about personal affairs (n=7) or requested an alternative opinion about their care (n=9).  
 
DISCUSSION  
This study demonstrates the considerable symptom burden, the influence of symptoms on HRQoL and the 
prognostic importance of HRQoL in relatively fit individuals, early in the disease course with MPM. 
Furthermore, individuals with MPM are seeking information from a wide support network, highlighting 
potentially important unmet needs.  
 
Despite the design of this study only including participants with good performance status (0 or 1), within the 
intervention arm, approximately 70% of participants presented with 3 or more symptoms, with 62% reporting a 
moderate to high severity of those symptoms. This is similar to other studies, which found that a third of all 
patients diagnosed with cancer, regardless of stage, had two or more symptoms22. The most common symptoms 
in this study were dyspnoea, pain and fatigue. The presence of dyspnoea, pain, anorexia, fatigue and/or weight 
loss was associated with a statistically significant difference in survival in univariable analysis.  
 
After adjustment for multiple clinical variables only the presence of pain remained statistically significant with a 
HR for death of 2.9 (95% CI 1.3-6.7; p=0.01). This is consistent with other studies and pain is recognised as a 
prognostic factor across many tumour types 12,14,15. Pain has a direct impact on HRQoL and perhaps disease 
outcomes, with theories about the release of tachykinins that may modulate immune function, or cause cyclo-
oxygenase mediated prostaglandin release 23,24. Additionally, the psychological impact of cancer pain is well 
established, with known links to significant psychological and physical impairment 25. The presence of pain has 
been significantly associated with depressive and anxiety symptoms in addition to poor overall quality of life 
and dissatisfaction with health care 25,26. Pain at presentation, even in patients with good performance status, 
could therefore be a trigger for consideration of referral to palliative care not only because of symptom burden, 
but because a quarter of patients had questions about prognosis or end of life care. These patients are likely to 
have a shorter survival and thus are likely to benefit from earlier opportunities for such advance care planning 
27. 
 
Fatigue was also a prominent physical symptom in our study, in common with other reports 28,29. It is a key 
physical symptom predictive of survival and an established unmet need within the cancer population 9,17. 
Fatigue is common, with up to 86% of participants in the intervention arm of our study reporting such (from the 
SPARC tool), and at least 27% reporting “tiredness” in the overall cohort (from the QLQ-C30). This is 
consistent with other studies, reporting rates between 61-94% 2,29. Fatigue is a difficult symptom to manage and 
is perhaps related to pro-inflammatory cytokines which are themselves related to the neutrophil-lymphocyte-
ratio and vascular endothelial growth factor 16. The impact of fatigue is greater than simply feeling tired as it 
impacts on both social and physical function, and functional independence 30.  
 
The social impact of a new diagnosis of MPM cannot be underestimated. A cancer diagnosis can lead to change 
in identity, role within the family unit, relationships and in some cases leads to social isolation10. There is often 
fear about becoming a burden to their families which is common in all cancer types9,17. This study confirms this 
for MPM patients, with 79.1% of participants worried about the effect of their illness on their families, and 
12.8% concerned that they might need more support than their family can provide. Participants were fearful of 
losing their independence (37.2%) and their ability to perform ADLs (23.3%) or household tasks (41.9%). 
Participants also turned to support outside their families, with 40% of participants identifying friends, including 
neighbours and work colleagues, as people they felt they could communicate their diagnosis with. Collectively, 
these data have a simple message, many patients with MPM (and their families) may need more support soon 
after the diagnosis and patients are fearful of impact on their families.  
 Most participants (65 of 87, 75%) had the opportunity to discuss their diagnosis and care with specialist nurses. 
The high proportion of participants reporting discussions with specialised thoracic nurses is likely a reflection of 
the recruiting specialist centres, all which had senior specialised thoracic cancer nurses, who play a key role in 
the early care and diagnosis of cancer patients 31,32. MPM is frequently associated with occupational exposure 
and thus there are often medicolegal and compensation implications to the diagnosis. Therefore, it is noteworthy 
that just seven participants mentioned seeking support from asbestos disease/mesothelioma support groups.  
This study may be either under reported, under-utilised or may reflect inadequate resourcing and represent an 
educational need for thoracic cancer nurses.   
 
This study demonstrated that for each unit increase in GHS (HRQoL) score, survival improved (HR for death 
0.987 (95% CI: 0.978 to 0.996), p=0.006). These results are consistent with other reports using other measures, 
Hollen et al 2, used the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso) tool to assess 
HRQoL and found that poor baseline overall QoL scores were associated with a shorter survival time, with loss 
of appetite and pain being significant predictors of survival. Nowak et al 3, found that baseline scores from the 
EORTC QLQ-C30 and lung cancer module-13 were significant predictors of survival, with fatigue and physical 
function being the strongest predictors. Kao et al 16, found a similar constellation of symptoms using LCSS-
Meso statistically significant for survival on multivariate analysis.  
 
As HRQoL is a reflection of physical, social and mental health, future work to address any modifiable aspects 
that influence QoL is required. For instance, this study highlights the unmet education and support needs of 
many patients with MPM (and their families) soon after the diagnosis of MPM, suggesting that improvements in 
clinical and support services may be required. Further trials such as the ANTHEM study, which will examine 
the efficacy of a Ghrelin agonist to treat weight loss and poor appetite in patients with MPM 33 are required to 
address modifiable physical symptoms. Finally, this study found that there is a good correlation between the 
different HRQoL measures that were used, which suggests it does not matter exactly which measure is used in 
this population, so long as a measure of QoL is used. 
 
Potential limitations should be considered when interpreting the data from this study, particularly, that of 
generalisability. Our study population was selected for their relatively good performance status and thus is not 
necessarily reflective of the wider population with MPM. Nevertheless, 108 (59%) of those recruited had a PS 
of 1 and the median survival for all participants was just 52 weeks, consistent with the expected survival of 
MPM1. Presumably, individuals with a worse PS at MPM diagnosis will have a higher burden of the same 
physical, psychological and emotional symptoms as well as unmet needs. These patients should be flagged as 
having a poor prognosis using simple decision tools 34to allow their primary carers to access relevant support in 
advanced care planning and end of life care strategies. 
 
Conclusion  
This study demonstrates that patients with mesothelioma have a high burden of symptoms, even at an early 
stage. Increasing physical symptoms and lower quality of life scores are associated with poor survival. Unmet 
needs are common and wide support networks are utilised to support mesothelioma patients and their families.  
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Table 1. Baseline characteristics 
 Standard Care (N=87)  Regular Early SPC (N=87) 
Numbers included  n  n  
Age Mean (SD)  87 73.2 (8.2)  87 72.4 (7.8)  
Gender Male (%)  87 72 (82.8) 87 67 (77.0) 
Histological subtype  
Non-Epitheliod/Epitheliod  
(% Non-Epitheliod/Epitheliod) 
87 19/68 
(21.8/78.2)  
87 19/68 
(21.8/78.2) 
Plan for chemotherapy Yes (%) 86 45 (52.3) 87 47 (54.0) 
ECOG performance status 0/1  
(% 0/1)  
87 32/55 
(36.8/63.2) 
87 34/53 
(39.1/60.9) 
SD – standard deviation; ECOG – Eastern Co-operative Oncology Group   
  
Table 2 - The relationship of the three most commonly reported symptoms mesothelioma and outcome. 
Reported 
symptoms from 
QLQ-C30 
Dyspnoea Pain Fatigue 
 
 No/a little quite/very 
much 
No/a little quite/very 
much 
No/a little quite/very 
much 
Number of deaths 
(%) 
59 (49.2) 34 (64.2) 66 (50.8) 26 (65.0) 60 (48.0) 32 (68.1) 
Median survival 
time in weeks 
(95% CI) 
65.3 (49.1, 
78.3) 
41.0 (28.1, 
69.0) 
59.4 (46.4, 
77.6) 
45.1 (22.4, 
67.3) 
67.3 (49.3, 
78.3) 
42.7 (24.0, 
54.7) 
Log rank test 0.01 0.03 0.002 
Hazard ratio (95% 
CI) 
1.7 (1.1-2.6) 1.7 (1.1-2.6) 1.9 (1.3-3.0) 
P-value (Cox PH) 0.02 0.03 0.003 
QLQ-C30 - European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 
30; CI – confidence interval 
  
Figure 1– Edmonton Symptom Assessment System (ESAS); symptoms by severity (graph) and frequency 
(table) (N=86) 
 
 
 
 
Figure 2. The relationship of baseline reported quality of life and survival 
 
  
 Figure 3 - The interrelationship of reported support networks for mesothelioma patients (from the five largest groups)   
 
 
 
 
 
